163 related articles for article (PubMed ID: 29740790)
1. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
2. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram Synergizes with SRC Inhibitors to Suppress the Growth of Pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo.
Li Z; Xie X; Tan G; Xie F; Liu N; Li W; Sun X
Biol Pharm Bull; 2021; 44(9):1323-1331. PubMed ID: 34471060
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Awasthi N; Hinz S; Brekken RA; Schwarz MA; Schwarz RE
Cancer Lett; 2015 Mar; 358(1):59-66. PubMed ID: 25527450
[TBL] [Abstract][Full Text] [Related]
5. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Kim I; Choi YS; Song JH; Choi EA; Park S; Lee EJ; Rhee JK; Kim SC; Chang S
Mol Oncol; 2018 Sep; 12(9):1526-1539. PubMed ID: 30055072
[TBL] [Abstract][Full Text] [Related]
6. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
7. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
8. The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma.
Hii LW; Lim SE; Leong CO; Chin SY; Tan NP; Lai KS; Mai CW
BMC Complement Altern Med; 2019 Sep; 19(1):257. PubMed ID: 31521140
[TBL] [Abstract][Full Text] [Related]
9. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
15. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
16. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract][Full Text] [Related]
17. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
18. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
19. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
[TBL] [Abstract][Full Text] [Related]
20. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Wallez Y; Dunlop CR; Johnson TI; Koh SB; Fornari C; Yates JWT; Bernaldo de Quirós Fernández S; Lau A; Richards FM; Jodrell DI
Mol Cancer Ther; 2018 Aug; 17(8):1670-1682. PubMed ID: 29891488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]